Core Viewpoint - Shanghai Fosun Pharmaceutical Group Co., Ltd. is responding to regulatory inquiries regarding its investment in Green Valley Pharmaceutical, particularly focusing on the uncertainties surrounding the commercialization and clinical trials of its main product, Ganluo Sodium Capsules, which is aimed at treating Alzheimer's disease. Group 1: Investment and Financial Aspects - The company plans to invest a total of 14.12 billion yuan to gain controlling interest in the target company [3] - The acquisition is expected to result in significant goodwill, which may be subject to impairment risks if the clinical trials do not meet expectations [3][4] - As of September 30, 2025, the target company reported total assets of 806 million yuan and liabilities of 795 million yuan, indicating a very low equity position [25] Group 2: Product Development and Clinical Trials - Ganluo Sodium Capsules received conditional approval from the National Medical Products Administration (NMPA) in November 2019 for treating mild to moderate Alzheimer's disease [6] - The product's registration certificate is set to expire in November 2024, and the company must complete ongoing post-marketing confirmatory clinical trials to resume commercialization [24] - The ongoing confirmatory clinical trial aims to enroll 1,950 patients, with 580 already enrolled as of December 15, 2025, and is expected to complete by the end of 2027 [19] Group 3: Regulatory Challenges and Market Competition - The NMPA did not approve the extension of the product's registration due to the ongoing clinical trials, which raises uncertainties about the product's future [10] - The market for Alzheimer's treatments is becoming increasingly competitive, with multiple products either already on the market or in development, which could impact the sales of Ganluo Sodium Capsules [3][4] - The company has implemented various risk control measures to address potential issues related to the product's efficacy and safety during the clinical trial process [17] Group 4: Compliance and Legal Issues - The target company faced administrative penalties for improper sales practices, which were confirmed during due diligence, but these penalties have not significantly impacted its operations [29][30] - The company has established a compliance framework to manage marketing activities and ensure adherence to regulatory standards following the acquisition [30]

Core Viewpoint - The acquisition of Green Valley Pharmaceutical by Fosun Pharma is a strategic move to gain control over the Alzheimer's drug "Jiuyiqi" (Mannose Sodium Capsules), which has faced regulatory challenges and production halts, reflecting both potential opportunities and significant risks in the CNS disease market [1][3][4]. Company Summary - Fosun Pharma plans to invest approximately 1.412 billion RMB to acquire a 53% stake in Green Valley Pharmaceutical, which will be consolidated into Fosun's financial statements post-acquisition [1]. - The core asset of this acquisition is the drug "Jiuyiqi," which has been halted from commercial production due to regulatory issues, specifically the expiration of its drug registration certificate in November 2024 [1][4]. - Green Valley's revenue for the first three quarters of 2025 was only 102 million RMB, with a net loss of 67.61 million RMB, indicating a significant decline in its financial health [1][4]. Industry Summary - The Alzheimer's drug market is characterized by high unmet clinical needs, with approximately 17 million patients in China and projected social costs reaching 3.2 trillion RMB by 2030 [9]. - "Jiuyiqi" has been surrounded by controversy regarding its efficacy and regulatory compliance, leading to a halt in its production and a rise in black market activity due to supply shortages [4][5]. - The acquisition is part of Fosun's broader strategy to enhance its portfolio in the CNS disease sector, which includes investments in diagnostic and therapeutic technologies [6][7].

Core Viewpoint - Fosun Pharma announced the acquisition of a 53% stake in Green Valley (Shanghai) Pharmaceutical Technology Co., Ltd. for approximately 1.412 billion yuan, making it a subsidiary of Fosun Pharma. This acquisition is a strategic move to enhance its presence in the central nervous system treatment sector, particularly focusing on Alzheimer's disease [1][2]. Group 1: Acquisition Details - The acquisition aims to integrate Green Valley's core product, Manzhuan Sodium Capsules (brand name "Jiuqi Yi"), into Fosun Pharma's innovative drug pipeline, targeting mild to moderate Alzheimer's disease [1][2]. - Fosun Pharma plans to support the post-marketing confirmatory clinical research for Manzhuan Sodium Capsules to expedite its approval process [1][3]. Group 2: Product and Market Context - Manzhuan Sodium Capsules are derived from marine brown algae and were conditionally approved as a Class 1 new drug by the National Medical Products Administration in November 2019 for improving cognitive function in Alzheimer's patients [2]. - The product was included in the national medical insurance catalog in 2021, but due to incomplete post-marketing confirmatory clinical research, the drug's registration certificate will expire in November 2024, halting commercial production [2]. Group 3: Future Plans and Research - Fosun Pharma intends to enhance its research and development efforts, focusing on comprehensive management treatment solutions that include early screening, medical diagnosis, drug intervention, and non-invasive treatment devices [2]. - The company is committed to conducting the necessary post-marketing confirmatory clinical trials under the guidance of drug regulatory authorities to ensure the quality and integrity of the trial data [3].

Core Viewpoint - The company aims to enhance its product pipeline in the central nervous system treatment area by acquiring a controlling stake in Green Valley Pharmaceutical, focusing on unmet clinical needs and creating integrated diagnostic and therapeutic solutions [2][7][48]. Transaction Overview - The total investment for the acquisition amounts to 1.412481633 billion yuan, which includes: - 143 million yuan for acquiring 20.15 million yuan of registered capital from existing shareholders [2][7]. - 1.269481633 billion yuan for subscribing to 200.867347 million yuan of newly registered capital [2][7]. - The acquisition will result in the company holding 53% of the target company's shares post-transaction, integrating it into the company's consolidated financial statements [3][48]. Company Background - The target company, established in October 2018, focuses on the research, production, and sales of drugs for neurodegenerative diseases, particularly the drug Mannothe Sodium Capsule, which has shown efficacy in improving cognitive function in Alzheimer's patients [13][14][47]. - The drug received conditional approval from the National Medical Products Administration in November 2019 and was included in the national medical insurance catalog in 2021 [13][47]. Financial Data - As of December 31, 2023, the target company reported total assets of 1.08089 billion yuan and a net profit of 31.48 million yuan [14]. - The financial outlook shows a decline in revenue and profit due to the expiration of the drug's registration certificate in November 2024, which halted commercial production [14][48]. Market Context - The global Alzheimer's disease patient population is projected to increase from 57 million in 2019 to 153 million by 2050, indicating a significant market opportunity [46]. - In China, the incidence rate of Alzheimer's disease has risen dramatically, with a reported increase of 242.5% from 1990 to 2021 [46]. - The market for Alzheimer's treatment drugs is expected to reach approximately 2.094 billion USD globally in 2024, with only 1.244 billion yuan in sales projected for China [46]. Strategic Intent - The acquisition is part of the company's strategy to address unmet clinical needs in the central nervous system treatment sector and to expand its product offerings [48]. - The company plans to continue clinical trials for the Mannothe Sodium Capsule to obtain necessary approvals for commercial production and to explore international clinical research opportunities [48].

Core Viewpoint - Fosun International (00656.HK) announced an agreement to acquire a stake in Green Valley (Shanghai) Pharmaceutical Technology, enhancing its position in the Alzheimer's disease treatment market [1][2]. Group 1: Acquisition Details - Fosun Pharma's subsidiary will acquire a total of 8.6667% equity in Green Valley, with a purchase price of RMB 143 million, and will subscribe to an additional capital increase of RMB 1,269,481,633, resulting in a total ownership of 46.3504% post-transaction [1]. - The transaction involves a special purpose vehicle (SPV) where Fosun Pharma and the founders will hold 51% and 49% stakes, respectively, facilitating the handling of employee stock buybacks [2]. Group 2: Market Context - Alzheimer's disease (AD) is a significant public health challenge with limited treatment options, and the market for AD treatments in China is underdeveloped, presenting substantial growth opportunities [3]. - The global sales for AD treatments are projected to reach approximately USD 2.094 billion in 2024, while the sales in China are expected to be only RMB 1.244 billion [3]. Group 3: Product Pipeline - The target company's Mannoheptulose capsules are indicated for mild to moderate Alzheimer's disease, showing significant cognitive improvement in clinical trials [4]. - Fosun Pharma is committed to advancing its product pipeline in the central nervous system disease sector, including ongoing clinical trials and the introduction of innovative treatment technologies [4].

Core Viewpoint - Fosun International announced an agreement to acquire a stake in Green Valley (Shanghai) Pharmaceutical Technology, enhancing its position in the Alzheimer's disease treatment market [1][2][3] Group 1: Acquisition Details - Fosun Pharma will acquire a total of 8.6667% of Green Valley's shares, with a purchase price of RMB 143 million, and will subscribe to additional registered capital amounting to RMB 1.269 billion, resulting in a total ownership of 46.3504% post-transaction [1][2] - The transaction involves a special purpose vehicle (SPV) where Fosun Pharma and the founders of Green Valley will hold 51% and 49% stakes, respectively, to manage employee buyback arrangements [2] Group 2: Market Context - Alzheimer's disease (AD) is a significant public health challenge with limited treatment options, and the market for AD treatments in China shows substantial growth potential, with a current sales figure of RMB 1.244 billion for 2024 [3][4] - The market for AD treatments globally is projected to reach USD 2.094 billion in 2024, indicating a strong demand for effective therapies [3] Group 3: Product Pipeline - Green Valley's Mannoheptulose capsules are aimed at treating mild to moderate Alzheimer's disease, showing significant cognitive improvement in clinical trials [4] - Fosun Pharma is expanding its product pipeline in the central nervous system disease sector, including non-invasive diagnostic and therapeutic solutions, and plans to conduct further clinical trials for the newly acquired drug [4]

Core Viewpoint - Fosun Pharma is acquiring a controlling stake in Green Valley Pharmaceutical for approximately RMB 1.412 billion, aiming to integrate its Alzheimer's drug, GV-971, into its innovative drug pipeline, despite the drug facing operational challenges and controversies since its launch in 2019 [1][2][3]. Company Summary - Fosun Pharma's acquisition will result in Green Valley becoming a subsidiary, with Fosun holding 53% of its shares post-transaction [5][6]. - The investment will be allocated to clinical research and daily operations of Green Valley, which has been under financial pressure and facing supply issues for GV-971 [1][5]. - The acquisition is seen as a strategic move for Fosun to enter the cognitive disorder treatment market and enhance its position in the neurodegenerative disease sector [4][10]. Industry Summary - The Alzheimer's drug market is experiencing significant activity, with recent approvals of two new targeted therapies, highlighting the competitive landscape [3][9]. - There is a substantial unmet clinical need for effective Alzheimer's treatments, as current options are limited and the disease poses a major public health challenge [5][9]. - The global pharmaceutical industry has invested over $600 billion in Alzheimer's research, with a high failure rate in drug development, indicating the complexities involved in this field [9][11]. - The Chinese government is prioritizing Alzheimer's disease management, with plans to enhance screening and intervention strategies by 2030, which may increase market opportunities [10].

作者 |第一财经 林志吟 因阿尔茨海默病（AD）药物"九期一"注册证到期而陷入停产的绿谷（上海）医药科技有限公司（"绿谷 医药"），迎来了接盘方。 12月15日，复星医药（600196.SH；02196.HK）宣布，控股子公司复星医药产业与绿谷医药及其现有相 关股东共同签订相关投资协议，拟出资约14.12亿元控股收购绿谷医药。 本次收购完成后，绿谷医药将成为复星医药控股子公司，其核心药品甘露特钠胶囊（商品名"九期一"） 也将纳入复星医药创新药品管线，主要用于治疗轻度至中度阿尔茨海默病（AD）。 2025.12.15 本文字数：961，阅读时长大约2分钟 甘露特钠胶囊重新开展商业化生产和销售前，还需（其中主要包括）补充完成目前尚在开展的上市后确 证性临床试验并获得国家药品审评部门批准。 复星医药方面表示，目前，研究团队正在积极开展甘露特钠胶囊上市后确证性临床试验。本次收购完成 后，复星医药将携绿谷医药团队在药品审评部门的指导下，有序严谨推进上市后确证性临床试验，以期 尽快实现获批；并适时开展相关适应证的国际多中心临床试验，惠及更多阿尔茨海默病患者。 复星医药CEO兼总裁刘毅表示，本次对绿谷医药的投资，是复星医药 ...

12月15日，复星医药（600196）公告，控股子公司复星医药产业拟出资共计14.12亿元控股投资绿谷医药。复星医药产业拟以自筹资金支付本次收购的对 价。 公告显示，此次收购完成后，复星医药将通过复星医药产业及SPV合计持有标的公司53%的股权，标的公司将纳入集团合并报表子公司范围。 若后续转让完成，公司将通过复星医药产业持有标的公司51%的股权，标的公司仍为集团合并报表子公司。 据了解，标的集团主要从事神经退行性疾病治疗药品的研发、生产和销售。 2019年11月，标的集团的甘露特钠胶囊获国家药监局有条件批准上市，获批适应症为"用于轻度至中度阿尔茨海默病，改善患者认知功能"；2021年，该药 品获纳入国家医保目录。 记者注意到，甘露特钠胶囊自2019年上市以来一直存在学术争议，其作用机制的相关论文，以及临床试验过程、临床疗效等均受到质疑。 2020年4月份，美国FDA批准了甘露特钠国际多中心Ⅲ期临床试验。该项试验设计在中国、美国以及欧洲招募2046人。绿谷在2022年5月宣布停止了甘露特 钠的国际三期临床试验，给出的原因是疫情、资金等因素影响。 今年5月起，甘露特钠胶囊陆续传出断供的消息。5月19日，绿谷方面 ...

Core Viewpoint - Fosun Pharma is focusing on unmet clinical needs in the central nervous system treatment area by investing a total of 1.41 billion yuan in Green Valley Pharmaceutical to enhance its innovative product pipeline and market layout [1] Group 1: Investment Details - Fosun Pharma's subsidiary plans to invest 143 million yuan to acquire 20.15 million yuan of registered capital from existing shareholders [1] - An additional investment of 1.27 billion yuan will be made to subscribe for 200.87 million yuan of new registered capital [1] Group 2: Shareholder Arrangements - The target company will first pay relevant buyback amounts to certain employees, with existing shareholders transferring 8.67 million yuan of registered capital to a newly established SPV at a nominal price [2] - After the completion of the acquisition, Fosun Pharma will hold a combined 53% stake in the target company, which will be included in the consolidated financial statements [2] Group 3: Product Information - The target group specializes in the research, production, and sales of drugs for neurodegenerative diseases, with its main product, Ganluo Sodium Capsule, conditionally approved for Alzheimer's treatment [3] - The drug has shown significant cognitive improvement in patients with mild to moderate Alzheimer's disease, particularly in moderate cases, based on clinical trial results [3] - Commercial production of the drug is currently on hold due to the expiration of its registration certificate, pending the completion of post-marketing confirmatory clinical trials [3]